Ob/Gyn Panel Unanimously Supports Adhesion-Prevention Product Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter's biosurgery business stands to gain from an FDA advisory panel's unanimous support for a product designed to prevent a serious side effect of certain surgical procedures. But limitations recommended for the label could curb some of the market potential if adopted by the agency in its final approval decision
You may also be interested in...
Tyco Acquires Bio-Sealant Pipeline With $245 Mil. Confluent Surgical Buy
Tyco Healthcare subsidiary U.S. Surgical will acquire Confluent Surgical for $245 mil. to augment its suture business with a pipeline of bioabsorbable sealants
Tyco Acquires Bio-Sealant Pipeline With $245 Mil. Confluent Surgical Buy
Tyco Healthcare subsidiary U.S. Surgical will acquire Confluent Surgical for $245 mil. to augment its suture business with a pipeline of bioabsorbable sealants
FDA Panel To Decide If Adept Adhesion Prevention Device Is True To Its Name
FDA's Obstetrics & Gynecology Devices Panel will consider Innovata's Adept for preventing gynecological laparoscopic surgery-based adhesions at a March 27 meeting in Gaithersburg, Md